Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $9.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 123.19% to $9.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.6 million, a 123.19% increase, with the full-year FY2024 number at $5.0 million, up 311.67% from a year prior.
  • Shares Outstanding (Weighted Average) was $9.6 million for Q3 2025 at Vivos Therapeutics, up from $9.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $21.2 billion in Q4 2021 to a low of $849446.0 in Q3 2022.
  • A 5-year average of $3.2 billion and a median of $5.0 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 165118.76% in 2021, then tumbled 100.0% in 2022.
  • Vivos Therapeutics' Shares Outstanding (Weighted Average) stood at $21.2 billion in 2021, then tumbled by 100.0% to $920592.0 in 2022, then surged by 32.46% to $1.2 million in 2023, then skyrocketed by 311.67% to $5.0 million in 2024, then skyrocketed by 90.39% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Outstanding (Weighted Average) are $9.6 million (Q3 2025), $9.1 million (Q2 2025), and $8.6 million (Q1 2025).